DCGI
DCGI extends shelf life of Covishield from 6 to 9 months
In a letter to the Serum Institute, DCGI said it is permitted to apply the shelf life of nine months to unlabelled vials available on hand
DCGI issues notice to Serum Institute over AstraZeneca's trial suspension
DGCI sought an immediate reply, saying else "it shall be construed that you have no explanation to offer and action will be taken"
Serum-Oxford COVID-19 vaccine gets DCGI grant for human trials in India
The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India
Hetero launches COVID-19 drug Favivir at Rs 59 per tablet
The product is available from July 29 at all retail medical outlets across the country and will be sold only on prescription, it said
FabiFlu more economical, effective treatment option for COVID-19: Glenmark tells DGCI
Glenmark also denied making any claims that “favipiravir alone” is effective in treatment of mild-to-moderate COVID-19 patients
Biophore gets DCGI nod to manufacture, export Favipiravir
CEO of Biophore said all starting materials for making favipiravir are either sourced locally or have been developed in-house for use
Hetero gets DCGI nod to launch Remdesivir for COVID-19 treatment
The drug will be available in 100 mg vial which will be administered intravenously in a hospital under healthcare practitioner supervision
8 Chinese companies get notices for poor quality of APIs
According to a pharma industry body, Indian pharma companies secure 70-75 per cent of APIs from China.